**Supplemental Digital Content 1 - Table 1**. Demographic and clinical characteristics of subjects at the initiation of cART, by cohort

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | AHOD, n=1036 | TAHOD, n=1121 | All patients, n=2157 |
| Age at cART initiation, median years (IQR) | 38 (32, 46) | 36 (30, 42) | 37 (31, 44) |
| Gender |  |  |  |
| Male | 981 (95%) | 840 (75%) | 1821 (84%) |
| Female | 55 (5%) | 281 (25%) | 336 (16%) |
| Reported route of infection |  |  |  |
| Homosexual contact | 784 (76%) | 353 (31%) | 1137 (53%) |
| Injecting drug use | 68 (6%) | 27 (2%) | 95 (4%) |
| Heterosexual contact | 111 (11%) | 662 (59%) | 773 (36%) |
| Other/unknown | 73 (7%) | 79 (7%) | 152 (7%) |
| Prior AIDS diagnosis at cART initiation |  |  |  |
| No | 921 (89%) | 722 (64%) | 1643 (76%) |
| Yes | 115 (11%) | 399 (36%) | 514 (24%) |
| Hepatitis B coinfection |  |  |  |
| No | 811 (94%) | 798 (90%) | 1609 (92%) |
| Yes | 52 (6%) | 89 (10%) | 141 (8%) |
| Not tested | 173 | 234 | 407 |
| Hepatitis C coinfection |  |  |  |
| No | 824 (89%) | 749 (93%) | 1573 (91%) |
| Yes | 103 (11%) | 59 (7%) | 162 (9%) |
| Not tested | 109 | 313 | 422 |
| CD4 T-cell count at cART initiation, median cells/μL (IQR) | 290 (170, 462) | 139 (44, 231) | 206 (89, 359) |
| Viral loadat cART initiation, median copies/mL (IQR) | 88017 (21112, 306900) | 86000 (19412, 329000) | 87600 (20595,313500) |
| Initial cART |  |  |  |
| NRTIs+NNRTI | 466 (45%) | 702 (63%) | 1168 (54%) |
| NRTIs+PI | 494 (48%) | 402 (36%) | 896 (42%) |
| Other combination | 76 (7%) | 17 (1%) | 93 (4%) |

Data are frequencies and within cohort region percentages in parentheses, unless otherwise indicated. cART; combination antiretroviral treatment, IQR; interquatile range, NRTIs; nucleoside/nucleotide reverse transcriptase inhibitors, NNRTI; non-nucleoside reverse transcriptase inhibitor, PI; protease inhibitor